CHALLENGES IN HEALTH ECONOMIC MODELING OF FEMALE-SPECIFIC HEALTH CONDITIONS

Author(s)

Ellen Telfer-Thomas, BSc, Laura Kelly, MSc, Angel Varghese, MSc.
York Health Economics Consortium, York, United Kingdom.
OBJECTIVES: Evaluating female-specific health conditions within health economic models is often constrained by poor-quality, inconsistent, or absent evidence, limiting the robustness of cost-effectiveness analyses. This research aims to identify the key challenges affecting economic evaluation of female-specific conditions within the United Kingdom by establishing common themes and their implications for health economic modelling.
METHODS: A pragmatic and targeted literature search was conducted within published studies and clinical guidelines for female-specific conditions. Recurring challenges were extracted.
RESULTS: Several recurring challenges were identified. Firstly, diagnostic delay was commonly reported. This resulted in women moving between primary and secondary care and receiving multiple or incorrect diagnoses before confirmation, limiting accurate capture of disease progression and costs. Secondly, a lack of standardised diagnostic criteria was across clinicians, trusts, and regions was found. This contributes to uncertainty in prevalence estimates and heterogeneous patient populations, complicating identification of representative cohorts. Thirdly, dedicated clinical guidance remained sparse for many conditions. For example, Fowler's syndrome, a recognised cause of chronic urinary retention, lacks a defined treatment pathway, complicating modelling of comparators and long-term outcomes. Lastly, condition-specific quality-of-life data were scarce. Evaluations often relied on symptom-based utility values, particularly for chronic pain, rather than condition-specific utilities, adding uncertainty to QALY estimates.
CONCLUSIONS: These challenges constrain both population health outcomes and the evidence base needed to demonstrate intervention value for female-specific health conditions. Establishing clear clinical definitions and care pathways would support improved guidance and data generation. However, this requires dedicated research investment to reduce avoidable uncertainty in future economic evaluations.

Conference/Value in Health Info

2026-11, ISPOR Europe 2026, Vienna, Austria

Value in Health, Volume 29, Issue 12S

Code

EE453

Topic

Economic Evaluation, Health Technology Assessment, Medical Technologies

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×